Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2009

View Archived Issues

Inhibitors of apoptosis inhibitor proteins (IAP) disclosed at Genentech for cancer

Thyroid-stimulating hormone receptor agonists created at NIH

N. lactamica outer membrane vesicle meningococcal vaccine tested in phase I study

Novel IKK2-inhibiting compounds tested for antiarthritic potential at GlaxoSmithKline

Pure androgen receptor antagonist CH-4933468 developed at Chugai

Inhibitors of CDK1, CDK5 and GSK-3 with anticancer activity developed at CNRS

Novel compounds for menopausal syndrome and oral contraception claimed by Bayer Schering Pharma

Wellstat Therapeutics claims compounds for treating type 2 diabetes

Lilly describes glucocorticoid receptor agonists for rheumatoid arthritis

Cannabinoid receptor ligands created for pain therapy at Purdue Pharma

Wyeth presents novel benzofuran analogues designed to inhibit NE reuptake

Cephalon details discovery and testing of c-Met inhibitors for cancer

Taspoglutide improves glycemic control in patients unresponsive to metformin

AstraZeneca Canada files NDS for FluMist vaccine

AMG-386 active and well tolerated in patients with advanced solid tumors

Health Canada approves Rituxan for treatment of CLL

Novel aromatase inhibitors claimed for cancer

The NIH awards grant to Advaxis for dual antigen vaccine

Yakult's Elplat approved for postoperative adjuvant chemotherapy of colon cancer

FDA approves two NDAs for Lundbeck's Sabril for IS and CPS

Biovail acquires U.S. and Canadian rights to develop and commercialize Santhera's fipamezole

Potential benefits for Avastin in second-line setting

Novartis' Xolair approved for severe persistent allergic asthma in children aged 6 to 11

FDA accepts for filing Cell Therapeutics' NDA for pixantrone in NHL

UCB and Novartis sign licensing agreement for cardiovascular, diabetes drugs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...